RET and non-small cell lung carcinoma: Almost 13 RET+ advanced NSCLC patients progressing on selpercatinib underwent plasma ± tissue biopsy, and eight patients presented evaluable results: two patients presented RET G810 solvent front resistance mutations, while one patient presented MET amplification [71].